Skip to main content
Clinical Trials/NCT06623097
NCT06623097RecruitingNot Applicable

Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study

Dana-Farber Cancer Institute2 sites in 1 country1,528 target enrollmentStarted: July 23, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
1,528
Locations
2
Primary Endpoint
Change in Global Cognition

Study Overview

Brief Summary

This research study will compare the impact of virtually supervised and unsupervised home-based exercise and diet programs on cognitive and physical function among cancer survivors and support persons. This study will involve a 6-month home-based virtually supervised or unsupervised exercise and diet intervention.

The names of the study interventions involved in this study are:

  • Virtually supervised exercise and healthy diet care
  • Unsupervised exercise and healthy diet care

Detailed Description

This is a multi-center, parallel arm, comparative effectiveness trial to compare the impact of supervised and unsupervised home-based exercise and diet programs on cognitive function and physical function among cancer survivors and support persons.

Participants and support persons in this study will be randomly assigned to one of two groups: Group A: Virtually Supervised Care or Group B: Unsupervised Care. Randomization means a participant is placed into a study group by chance.

The research study procedures include screening for eligibility, in-clinic visits, evaluations of fitness, physical health, diet, and cognitive function, surveys, and questionnaires.

Participation in this study is expected to last 12 months.

It is expected about 1528 people will participate in this research study.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •for Survivor Participants:
  • •Ability to understand and the willingness to sign informed consent prior to any study- related procedures.
  • •Older adults (≥65 years of age); cancer survivors who are at higher risk for developing comorbid conditions related to physical and cognitive function due to age declines.
  • •Completed chemotherapy and/or targeted therapy in the previous 36 months; said treatment exposure negatively impacts cognitive and physical function.
  • •Diagnosed with breast, lung, prostate, or colorectal cancer which are obesity-related cancers with higher risk for developing comorbid conditions related to physical and cognitive function.
  • •No detection of dementia as measured by scoring ≥ 23/41 on the Telephone Interview for Cognitive Status (TICS); it may be unsafe for individuals with dementia to participate in the intervention, and they may not be able to experience measurable cognitive improvement. Additionally, scores on cognitive measures could reflect task comprehension failure - not actual cognitive ability - as individuals with dementia may not be able to comprehend or follow the test instructions
  • •Overweight/obese: BMI ≥25 kg/m2 (calculated using height and weight) or body fat >35% for people assigned female at birth and >25% for people assigned male at birth (estimated by bioelectrical impedance); higher body weight negatively impacts cognitive and physical function.
  • •Currently participating in <60 minutes of structured moderate-to-vigorous exercise per week (determined by screening questionnaire); sedentary cancer survivors have a higher need and are more likely to benefit from exercise exposure.
  • •No history of disordered eating; to avoid triggering of past eating disorders with a diet intervention program.
  • •Reside with an (≥18 years of age) informal support person willing to participate; survivor/support person dyads will participate in the trial together per the goals of the trial and finding mechanism.
  • •Speak English or Spanish; the study teams will only be able to accommodate for these two languages at this time.
  • •Willing to travel to the respective site for necessary data collection.
  • •Inclusion Criteria for Support Person:
  • •Adults ≥18 years of age; the intervention is not designed for adolescent and pediatric populations.
  • •No detection of dementia as measured by scoring ≥ 23/41 on the Telephone Interview for Cognitive Status (TICS); it may be unsafe for individuals with dementia to participate in the intervention, and they may not be able to experience measurable cognitive improvement. Additionally, scores on cognitive measures could reflect task comprehension failure - not actual cognitive ability - as individuals with dementia may not be able to comprehend or follow the test instructions
  • •No history of disordered eating; to avoid triggering of past eating disorders with a diet intervention program.
  • •Speak English or Spanish; the study teams will only be able to accommodate for these two languages at this time.

Exclusion Criteria

  • •for Survivor Participants:
  • •Adult cancer survivors less than 65 years of age.
  • •Survivors with a TICS score ≤ 22/41
  • •Survivors with a BMI <25 kg/m2 and body fat <35% for people assigned female at birth and <25% for people assigned male at birth.
  • •Survivors currently consuming a Mediterranean Diet or meeting 2 or more out of the following 3 Mediterranean eating pattern goals in the prior 6 weeks: ≥3 servings of vegetables per day, ≥ 3 servings of beans and legumes per week, or ≥ 1 serving of nuts per day.
  • •Survivors with unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Persons with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of participant safety, as well as because this study involves remote, home-based exercise where close supervision is not possible, participants with unstable medical conditions will be excluded. This will be evaluated through the PAR- Q.
  • •Subjects with severe psychiatric conditions such as Active Major Depression, Bipolar Disorder, significant Suicidal ideation, and an active substance use and/or substance abuse disorder; these conditions can 1) adversely affect important cognitive test measures and 2) the ability to complete certain circumscribed interventions in the study.
  • •Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
  • •Survivors receiving treatment for an active malignancy (exceptions are treatment for basal cell carcinoma. They may receive long term treatments for their diagnosed breast, lung, prostate or colorectal cancer including hormone therapy). This study is exclusively targeting survivors post-primary cancer treatment.
  • •Exclusion Criteria for Support Person:
  • •Support persons less than 18 years of age.
  • •Support persons with a TICS score ≤ 22/41
  • •Given the age range of support persons include those in childbearing years, people who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
  • •Support persons with unstable comorbidities that prevent participation in moderate-to- vigorous intensity exercise. Persons with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of participant safety, as well as because this study involves remote, home-based exercise where close supervision is not possible, participants with unstable medical conditions are excluded.
  • •Support persons with severe psychiatric conditions such as Active Major Depression, Bipolar Disorder, significant Suicidal ideation, and an active substance use and/or substance abuse disorder; these conditions can 1) adversely affect important cognitive test measures and 2) the ability to complete certain circumscribed interventions in the study.
  • •Support persons receiving treatment for an active malignancy or are less than 10 years from the completion of any cancer treatment (exceptions are treatment for basal cell carcinoma). This is to preserve the "role" of the cancer survivor in the dyad.

Arms & Interventions

Arm 1: Virtually Supervised Care Comparator

Experimental
  • Complete virtually supervised exercise sessions 3x weekly with their study partner.
  • Complete Mediterranean eating program coaching session 1x weekly.

Intervention: Supervised Exercise and Diet Program (Behavioral)

Arm 2: Unsupervised Care

Experimental
  • Receives exercise and diet intervention recommendations including 3x weekly workouts and healthy eating goals
  • Weekly recorded informative videos
  • 4x weekly supportive text messages
  • Study website access and interventional booklet

Intervention: Unsupervised Exercise and Diet Program (Behavioral)

Outcomes

Primary Outcomes

Change in Global Cognition

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

The Montreal Cognitive Assessment (MOCA) will also be used to assess global cognition.

Change in Cognitive Function

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

Cognitive function will be measured using the National Institutes of Health (NIH) toolbox (www.nihtoolbox.org). Within the NIH toolbox, executive function, immediate recall, memory, attention, working memory, and processing speed will be measured.

Change in Physical Function (6-minute walk test)

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

The 6-minute walk test is also conducted to assess aerobic endurance and capacity. Distance achieved during the 6-minute walk test is recorded in meters.

Change Physical Function (Short Physical Performance Battery [SPPB])

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

The SPPB is comprised of three sections: 1) balance with feet together, semi tandem, and full tandem is held for up to 10 seconds with no support (seconds); 2) usual gait speed over four meters is timed (seconds); and 3) chair stand where the time(s) to complete five chair sit-to-stands is recorded.

Change in Physical Function (Timed-Up-And-Go (TUG) Test)

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

The TUG test times how fast it takes a participant to stand up from a chair, walk around a cone placed three meters away from a chair where they start, and end in a seated position (seconds).

Change in Physical Function (Gait Speed)

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

Gait speed is assessed over a six-meter course with a flat surface, where the time to walk the 15 foot course at a usual and fast pace is recorded (seconds).

Change in Physical Function (Sit-to-Stand Test)

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

The sit-to-stand test involves participants completing as many sit-to-stands from a seated chair position to a standing position with full hip extension in 30 seconds.

Change in Physical Function (Grip Strength)

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

Grip strength is assessed using a hand-held dynamometer on the participant's dominant hand.

Change in Physical Function (Frailty)

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

Overall frailty will be assessed using the Rockwood model, a 42-item questionnaire, and the Fried model, a 5-item questionnaire.

Change in Physical Function (Cardiorespiratory Fitness)

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

Cardiorespiratory fitness will be assessed as VO2peak by a graded maximal bicycle exercise stress test.

Change in Physical Function (Muscular Strength)

Time Frame: From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up)

Muscular strength will be assessed using 1-Repetition Maximum (RM) and will be estimated from 10-RM muscular strength tests.

Secondary Outcomes

  • Accelerometer-Captured Physical Activity(From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up))
  • Patient-Reported Outcome: PROMIS-29 Quality of Life Questionnaire(From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up))
  • Patient-Report Outcome: PROMIS Cognitive Function Questionnaire(From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up))
  • Mediterranean Eating Pattern(From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up))
  • Alternate Mediterranean Diet Score (aMED)(From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up))
  • Carotenoid Scan(From baseline (month 0) to month 6 (post-intervention) to month 12 (follow-up))

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Christina Dieli-Conwright, PhD

Principal Investigator

Dana-Farber Cancer Institute

Study Sites (2)

Loading locations...

Similar Trials